Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration
Chiara Lonati(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Marco Moschini(Vita-Salute San Raffaele University), Marco Borghesi(University of Bologna), Francesco Soria(Medical University of Vienna), Wojciech Krajewski(Wroclaw Medical University), Maria Carmen Mir(Fundación Instituto Valenciano de Oncología), Anne Sophie Valiquette(Fundación Instituto Valenciano de Oncología), Sarah Einerhand(The Netherlands Cancer Institute), Tobias Klatte(Helios Hospital Bad Saarow), Giancarlo Marra(Royal Free London NHS Foundation Trust), Christian D. Fankhauser(University of Zurich), Paolo Gontero(Fondazione Ricerca Molinette), Luca Afferi(Universitat Autònoma de Barcelona), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Alberto Martini(The University of Texas MD Anderson Cancer Center), Renzo Colombo(University of Insubria), M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Roberto Carando(Luzerner Kantonsspital), Andrea Minervini(Azienda Ospedaliero-Universitaria Careggi), Philipp Baumeister(University of Lucerne), Francesco Montorsi(Vita-Salute San Raffaele University), Morgan Rouprêt(Sorbonne Université), Michael Rink(Marienkrankenhaus Hamburg), Jeremy Yuen‐Chun Teoh(Chinese University of Hong Kong), Agostino Mattei(Luzerner Kantonsspital), Alessandro Antonelli(University of Verona), Ekaterina Laukhtina(Sechenov University), Kees Hendricksen(The Netherlands Cancer Institute), Shahrokh F. Shariat(Universitätszahnklinik Wien), Rodolfo Hurle(IRCCS Humanitas Research Hospital), Paolo Umari(University College London), Claudio Simeone(University of Brescia), Andrea Necchi(Vita-Salute San Raffaele University), A. Masson-Lecomte(Université Paris Cité), Stefania Zamboni(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Gerald Bastian Schulz(University of British Columbia), A. Bajeot(Centre Hospitalier Universitaire de Toulouse), Roberto Contieri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 16
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688